Skip to main content

Biological activity of two botulinum toxin type A complexes (Dysport® and Botox®) in volunteers

A double-blind, randomized, dose-ranging study

An Erratum to this article was published on 02 July 2009

Abstract

Despite extensive clinical experience and published data regarding botulinum toxin, questions remain about the clinical substitution of one botulinum toxin formulation for another. In the case of Dysport® and Botox®, doseequivalence ratios ranging from 1:1 to 6:1 (Dysport:Botox) have been advocated. This dose-ranging, electroneurographic study investigated the dose equivalence, diffusion characteristics (spread) and safety of these two type-A toxins in 79 volunteers. Dysport and Botox caused significant and similar reductions in compound muscle action potential (CMAP) amplitude in the target muscle (extensor digitorum brevis, EDB) 2 weeks after injection, with effects persisting to the 12-week timepoint. For both products, the reduction in amplitude was increased with increasing doses and with increasing concentration. The effects of toxin on neighbouring muscles were much smaller and of a shorter duration than those on the target muscle, implying a modest spread of toxin. Unlike the target muscle, the effects were greater with the higher volume, suggesting this volume led to greater diffusion from the EDB. No adverse events were reported. Statistical modelling with CMAP amplitude data from the target muscle gave a bioequivalence of 1.57 units of Dysport:1 unit of Botox (95 % CI: 0.77–3.20 units). The data indicate that a dose-equivalence ratio of 3:1 was within the statistical error limits, but ratios over 3:1 are too high.

This is a preview of subscription content, access via your institution.

References

  1. Botox® summary of product characteristics. http://emc.medicines.org.uk/ (last accessed 20 June 2007)

  2. Dysport® summary of product characteristics. http://emc.medicines.org.uk/ (last accessed 20 June 2007)

  3. Vistabel® summary of product characteristics. http://emc.medicines.org.uk/ (last accessed 20 June 2007)

  4. Bihari K (2005) Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemiacial spasm dystonia, and hemifacial spasm. Curr Med Res Opin 21:433–438

    PubMed  Article  CAS  Google Scholar 

  5. Brin MF, Blitzer A (1993) Botulinum toxin: dangerous terminology errors. J R Soc Med 86:493–494

    PubMed  CAS  Google Scholar 

  6. Durif F (1995) Clinical bioequivalence of the current commercial preparations of Botulinum toxin. Eur J Neurol 2:17–18

    Article  Google Scholar 

  7. Friday D, Bigalke H, Frevert J (2002) In vitro stability of botulinum toxin complex preparations at physiological pH and temperature. Naunyn Schmiedebergs Arch Pharmacol 365(Suppl 2): Abstract 46

    Google Scholar 

  8. Hambleton P, Pickett AM (1994) Potency equivalence of botulinum toxin preparations. J R Soc Med 87:719

    PubMed  CAS  Google Scholar 

  9. Jankovic J (2004) Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 75:951–957

    PubMed  Article  CAS  Google Scholar 

  10. Kimura J (2001) Electrodiagnosis in diseases of nerve and muscle: principles and practice. Third edition. Oxford University Press, New York

  11. Marchetti A, Magar R, Findley L, Larsen JP, Pirtosek Z, Ruzicka E, Jech R, Slawek J, Ahmed F (2005) Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study. Mov Disord 20:937–944

    PubMed  Article  Google Scholar 

  12. Nussgens Z, Roggenkamper P (1997) Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol 235:197–199

    PubMed  Article  CAS  Google Scholar 

  13. Poewe W (2002) Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 72:430

    PubMed  CAS  Google Scholar 

  14. Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M (2002) Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 72:459–462

    PubMed  CAS  Google Scholar 

  15. Rosales RL, Bigalke H, Dressler D (2006) Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol 13(Suppl 1):2–10

    PubMed  Article  Google Scholar 

  16. Sampaio C, Costa J, Ferreira JJ (2004) Clinical comparability of marketed formulations of botulinum toxin. Mov Disord 19(Suppl 8):S129–S136

    PubMed  Article  Google Scholar 

  17. Sampaio C, Ferreira JJ, Simoes F, Rosas MJ, Magalhaes M, Correia AP, Bastos- Lima A, Martins R, Castro-Caldas A (1997) DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A – Dysport and Botox – assuming a ratio of 4:1. Mov Disord 12:1013–1018

    PubMed  Article  CAS  Google Scholar 

  18. Schantz EJ, Johnson EA (1992) Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 56:80–99

    PubMed  CAS  Google Scholar 

  19. Sesardic D, Leung T, Gaines Das R (2003) Role for standards in assays of botulinum toxins: international collaborative study of three preparations of botulinum type A toxin. Biologicals 31:265–276

    PubMed  Article  CAS  Google Scholar 

  20. Truong DD, Jost WH (2006) Botulinum toxin: Clinical use. Parkinsonism Relat Disord 12:331–355

    PubMed  Article  Google Scholar 

  21. Wohlfarth K, Goschel H, Frevert J, Dengler R, Bigalke H (1997) Botulinum A toxins: units versus units. Naunyn Schmiedebergs Arch Pharmacol 355:335–340

    PubMed  Article  CAS  Google Scholar 

  22. Wohlfarth K, Kampe K, Bigalke H (2004) Pharmacokinetic properties of different formulations of botulinum neurotoxin type A. Mov Disord 19 (Suppl 8):S65–S67

    PubMed  Article  Google Scholar 

  23. Wohlfarth K, Muller C, Sassin I, Comes G, Grafe S (2007) Neurophysiological double-blind trial of a botulinum neurotoxin type a free of complexing proteins. Clin Neuropharmacol 30:86–94

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to K. Wohlfarth MD, PhD.

Additional information

An erratum to this article is available at http://dx.doi.org/10.1007/s00415-009-5182-7.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Wohlfarth, K., Schwandt, I., Wegner, F. et al. Biological activity of two botulinum toxin type A complexes (Dysport® and Botox®) in volunteers. J Neurol 255, 1932–1939 (2008). https://doi.org/10.1007/s00415-008-0031-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-008-0031-7

Key words

  • botulinum toxin
  • Dysport
  • Botox
  • dose equivalence
  • randomized controlled trial